Related Experiment Videos
[Long-term sedation with propofol in ICU: hemocoagulation problems]
I Niccolai1, L Barontini, P Paolini
1U.O. Anestesia e Rianimazione, USSL 8, Pistoia.
Insights
This study found that long-term propofol sedation did not affect blood coagulation in ICU patients. Key coagulation markers remained stable across different treatment durations, indicating safety for critically ill individuals.
Area of Science:
- Anesthesiology
- Critical Care Medicine
- Hematology
Context:
- Propofol is a widely used anesthetic and sedative agent in intensive care units (ICUs).
- Long-term sedation with propofol is common for critically ill patients requiring mechanical ventilation.
- The potential impact of propofol on hemostasis requires thorough investigation.
Purpose:
- To evaluate the effects of long-term propofol sedation on various blood coagulation parameters in ICU patients.
- To determine if the duration of propofol administration influences coagulation.
- To assess the safety of propofol concerning hemostatic function.
Summary:
- Fifteen ICU patients receiving long-term propofol sedation (3 mg/kg/h) were analyzed.
- Coagulation variables including platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, Fibrin Degradation Products (FDP), and Antithrombin III (AT III) were monitored.
- No significant differences in coagulation parameters were observed before and after propofol administration, nor across patient groups with varying propofol exposure durations (1-3 days, 4-10 days, 11-35 days).
Impact:
- This research suggests that propofol, even with prolonged use in ICU settings, does not appear to adversely affect blood coagulation.
- Findings support the continued use of propofol for long-term sedation without major hemostatic concerns.
- Further research may explore specific patient populations or higher doses if needed.
Abstract:
The Authors have studied the effects of propofol on coagulation in 15 patients admitted to ICU. Propofol was used for long-term sedation (therapeutic range 3 mg/kg/h). Variables monitored included: platelets, PTT, PT, Fibrinogen, FDP, AT III. The effects on coagulation has been investigated in three groups of patients: group I) 5 patients that received propofol for 1-3 days; group II) 5 patients that received propofol for 4-10 days; group III) 5 patients that received propofol for 11-35 days. No difference were found about blood coagulation in this groups of patients before and after administration of propofol.